BioSpace News Archive

Amgen today announced the appointment of Amy E. Miles to its Board of Directors, effective July 23, 2020.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for vosoritide, an investigational, once daily injection analog of C-type Natriuretic Peptide (CNP) for children with achondroplasia,

Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.60 per share dividend for the third quarter of 2020. The dividend will be paid on September 8, 2020 , to all stockholders of record as of the close of business on August 17, 2020 . About Amgen Amgen is committed to unlocking the potential

eHealth, Inc. (NASDAQ: EHTH), a leading private online health insurance marketplace, announces today its financial results for the second quarter ended June 30, 2020.

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and webcast on July 30, 2020 at 4:30 pm ET (1:30 pm PT) to provide a business update and report second quarter 2020 financial results. The conference call can be accessed by dialing 1-855-327-6837 (toll-free domestic) or 1-631-891-4304 (international) and using the conference ID 10010533. T

Phosplatin Therapeutics LLC , a clinical stage pharmaceutical company focused on oncology therapeutics, today announced that the United States Patent and Trademark Office ( USPTO ) has issued US Patent No. 10,668,080, entitled: “Phosphaplatin Compounds as Therapeutics Agents for Treatment of Bone or Blood Cancers.” The granted claims are d

Chairman and CEO Kenneth L. Londoner to provide an update on the commercial rollout of PURE EP(tm) System, clinical development of BioSig’s pharmaceutical subsidiary and conduct virtual one-on-one meetings with investors

Evofem Biosciences, Inc. (NASDAQ: EVFM) will hold a webcast and conference call to discuss the Company’s financial results and business highlights for the second quarter ended June 30, 2020 .

AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today annou

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that it will host a conference call on Thursday, July 30, 2020, at 4:30 p.m. ET to discuss its financial results for the quarter and six months ended June 30, 2020, and recent operational highlights. To access the live call by phone, dial (